Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers.
暂无分享,去创建一个
[1] Yung-chi Cheng,et al. Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model , 2000, Antimicrobial Agents and Chemotherapy.
[2] Y. Cheng,et al. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. , 1999, Biochemical pharmacology.
[3] Y. Cheng,et al. Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein Barr virus agents. , 1999, Journal of medicinal chemistry.
[4] Z. Jiang,et al. Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria* , 1999, The Journal of Biological Chemistry.
[5] Shwu-Huey Liu,et al. Anti-Hepatitis B Virus Activity and Metabolism of 2′,3′-Dideoxy-2′,3′-Didehydro-β-l(−)-5-Fluorocytidine , 1998, Antimicrobial Agents and Chemotherapy.
[6] M. Kukhanova,et al. Metabolism of 2′,3′-Dideoxy-2′,3′-Didehydro-β-l(−)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Human Immunodeficiency Virus β-d(+) Nucleoside Analogs In Vitro , 1998, Antimicrobial Agents and Chemotherapy.
[7] Y. Cheng,et al. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.
[8] M. Kukhanova,et al. Interaction of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: implications for human immunodeficiency virus drug design. , 1998, Molecular pharmacology.
[9] M. Kukhanova,et al. Unique inhibitory effect of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil 5'-triphosphate on Epstein-Barr virus and human DNA polymerases. , 1998, Biochemical pharmacology.
[10] C. K. Chu,et al. Synthesis and Anti-Hepatitis B Virus Activity of 9-(2-Deoxy-2-fluoro-. beta.-L-arabinofuranosyl)purine Nucleosides. , 1997 .
[11] M. Newton,et al. Synthesis and Anti-Hepatitis B Virus Activity of 9-(2-Deoxy-2-fluoro-β-l-arabinofuranosyl)purine Nucleosides , 1997 .
[12] E. Gullen,et al. Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro , 1996 .
[13] M. Kukhanova,et al. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. , 1996, Biochemical pharmacology.
[14] Y. L. Zhu,et al. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil , 1996, Antimicrobial agents and chemotherapy.
[15] Y. Cheng,et al. Use of novel beta-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. , 1995, Progress in liver diseases.
[16] R. Schinazi,et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. , 1992, The Journal of biological chemistry.
[17] R. Schinazi,et al. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[18] C. H. Chen,et al. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. , 1991, Molecular pharmacology.
[19] C. H. Chen,et al. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. , 1989, The Journal of biological chemistry.